R03BA02 - Budesonide

Not porphyrinogenic

Rationale

Inducer of 3A5. Probably quantitatively insignificant metabolic exposure Several references stating non-porphyrinogenicity of glucocorticoids. Significant clinical experience of non-porphyrinogenicity.

Chemical description

Corticosteroide in inhalation aerosol (50 ug/dose)l, used in treatment of asthma. Systemic bioavailability about 26 %. Metabolized by CYP 3A4. C.Andersson, patient reports: tolerated (n=8). Used in porphyria ward (Sweden). glucocorticoids EPI-list: safe South African list: use Kalman, Bonkowski: safe The Merck Manual: safe Tschudy DP, Lamon JM: Porphyrin metabolism and the porphyrias, in Bondy PK, Rosenberg LE (eds.): Duncans Diseases of Metabolism. Philadelphia, WB Saunders, 1980, p939: safe Moore MR, Hift RJ: Drugs in the acute porphyrias. Cell Mol Biol 43:89, 1997: safe

IPNet drug reports

Uneventful use reported in 21 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes R03B / R03BA or go back.

References

#	Citation details	PubMed ID
1.	Management of acute attacks in the porphyrias. Kalman DR, Bonkovsky HL. Clin Dermatol. 1998; 16(2):299-306.	9554242
2.	Drugs in the acute porphyrias--toxicogenetic diseases. Moore MR, Hift RJ. Cell Mol Biol (Noisy-le-grand). 1997 Feb; 43(1):89-94.	9074793
Other sources
3.	Porphyrin metabolism and the Porphyrias [Book Chapter] Tschudy DP, Lamon JM Bondy BK, Rosenberg LE (eds): Duncan's Diseases of Metabolism, Philadelphia, WB Saunders. 1980.